[Metabolic imaging for supratentorial oligodendrogliomas].
Metabolic imaging with positron emission tomography (PET) provides, in neuro-oncology, information complementary to that provided by anatomic imaging obtained with CT-scanner or MRI. Only a few publications have yet reported its use in oligodendroglial tumors. These findings and partial results obtained in ongoing work, suggest some preliminary conclusions: 11C-MET (L-methyl-methionine) is a more appropriate tracer than 18F-FDG (fluoro-deoxy-glucose), in terms of both specificity and sensitivity, for the assessment of patients with this category of tumor. PET/MET allows differentiation between grade II and grade III oligodendrogliomas; better targeting for stereotactic biopsy; more accurate assessment of the post-operative residual tumor; identification of progression from low-grade to anaplastic grade during the disease course; differentiation between recurrence and a post-radiation processes. PET/MET allows, to some extent, prediction of response to radiotherapy; and, probably, to chemotherapy.
Derlon
J-M
JM
CHU et GIP Cyceron, Caen. derlon-jm@chu-caen.fr
Cabal
P
P
Blaizot
X
X
Borha
A
A
Chapon
F
F
D000328:Adult; D000596:Amino Acids / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis; D006801:Humans; D021621:Imaging, Three-Dimensional; D008279:Magnetic Resonance Imaging; D008297:Male; D008715:Methionine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D049268:Positron-Emission Tomography; D011849:Radioactive Tracers; D015173:Supratentorial Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D014057:Tomography, X-Ray Computed
D000596:Amino Acids; D011849:Radioactive Tracers; D008715:Methionine; C038344:methionine methyl ester; D005947:Glucose